ES2137350T3 - Formulacion farmaceutica. - Google Patents

Formulacion farmaceutica.

Info

Publication number
ES2137350T3
ES2137350T3 ES94901148T ES94901148T ES2137350T3 ES 2137350 T3 ES2137350 T3 ES 2137350T3 ES 94901148 T ES94901148 T ES 94901148T ES 94901148 T ES94901148 T ES 94901148T ES 2137350 T3 ES2137350 T3 ES 2137350T3
Authority
ES
Spain
Prior art keywords
pharmaceutical formulation
active agent
aqueous carrier
mpas
pursuant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94901148T
Other languages
English (en)
Other versions
ES2137350T7 (es
Inventor
Christer Nystrom
Lennart Paalzow
Sten-Magnus Aquilonius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neopharma AB
Original Assignee
Neopharma Production AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharma Production AB filed Critical Neopharma Production AB
Publication of ES2137350T3 publication Critical patent/ES2137350T3/es
Application granted granted Critical
Publication of ES2137350T7 publication Critical patent/ES2137350T7/es
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UNA FORMULACION FARMACEUTICA PARA ADMINISTRACION INTRADUODENAL CONSTA DE AL MENOS UN AGENTE FARMACOLOGICAMENTE ACTIVO, CON SOLUBILIDAD LIMITADA EN AGUA Y ESTA DISPERSADO EN UN PORTADOR ACUOSO. SEGUN LA INVENCION, EL AGENTE ACTIVO TIENE UN TAMAÑO DE PARTICULA QUE NO EXCEDE DE 20 NM, Y EL PORTADOR ACUOSO TIENE UNA VISCOSIDAD DE AL MENOS 300 MPAS, MEDIDA A UNA VELOCIDAD DE CORTE MODERADA.
ES94901148.0T 1992-11-30 1993-11-29 Formulación farmacéutica Active ES2137350T7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system
SE9203594 1992-11-30
PCT/SE1993/001029 WO1994012153A1 (en) 1992-11-30 1993-11-29 A pharmaceutical formulation

Publications (2)

Publication Number Publication Date
ES2137350T3 true ES2137350T3 (es) 1999-12-16
ES2137350T7 ES2137350T7 (es) 2017-11-13

Family

ID=20387973

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94901148.0T Active ES2137350T7 (es) 1992-11-30 1993-11-29 Formulación farmacéutica

Country Status (15)

Country Link
US (1) US5635213A (es)
EP (1) EP0670713B3 (es)
JP (1) JP3661703B2 (es)
AT (1) ATE184191T3 (es)
AU (1) AU688290B2 (es)
CA (1) CA2150464C (es)
DE (2) DE122005000021I1 (es)
DK (1) DK0670713T3 (es)
ES (1) ES2137350T7 (es)
FR (1) FR04C0024I2 (es)
GR (1) GR3031988T3 (es)
NL (1) NL300169I1 (es)
NZ (1) NZ258276A (es)
SE (1) SE9203594D0 (es)
WO (1) WO1994012153A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
JP4653893B2 (ja) * 2000-01-27 2011-03-16 純一 須藤 二層型経皮吸収製剤
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005053796A1 (en) * 2003-12-02 2005-06-16 B & B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
RU2484815C2 (ru) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2653179B1 (en) 2012-04-17 2019-07-10 Micrel Medical Devices S.A. System for calculating and administering a drug to a patient with Parkinson's disease
ES2973289T3 (es) 2014-09-04 2024-06-19 Lobsor Pharmaceuticals Ab Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX393568B (es) 2014-10-21 2025-03-24 Abbvie Inc Profarmacos de carbidopa y l-dopa y metodos de uso
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
BR112019001082A2 (pt) * 2016-07-20 2019-04-30 Abbvie Inc. gel intestinal de levodopa e carbidopa e métodos de uso
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
AU2019237857B2 (en) 2018-03-23 2024-11-21 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
UY38473A (es) 2018-11-15 2020-06-30 Abbvie Inc Formulaciones farmacéuticas para una administración subcutánea

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
US4356824A (en) * 1980-07-30 1982-11-02 Vazquez Richard M Multiple lumen gastrostomy tube
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8720600D0 (en) * 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
FR04C0024I2 (es) 2010-12-31
ATE184191T3 (de) 1999-09-15
JPH08504764A (ja) 1996-05-21
DK0670713T3 (da) 2000-03-20
EP0670713A1 (en) 1995-09-13
DE69326350T3 (de) 2018-01-11
SE9203594D0 (sv) 1992-11-30
CA2150464C (en) 2002-02-05
EP0670713B1 (en) 1999-09-08
FR04C0024I1 (es) 2004-03-12
DE69326350D1 (de) 1999-10-14
GR3031988T3 (en) 2000-03-31
DE69326350T2 (de) 2000-01-27
WO1994012153A1 (en) 1994-06-09
NL300169I1 (nl) 2005-03-01
NZ258276A (en) 1996-09-25
US5635213A (en) 1997-06-03
DE122005000021I1 (de) 2006-02-23
AU688290B2 (en) 1998-03-12
CA2150464A1 (en) 1994-06-09
ES2137350T7 (es) 2017-11-13
JP3661703B2 (ja) 2005-06-22
AU5583694A (en) 1994-06-22
EP0670713B3 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
CA2150464A1 (en) A pharmaceutical formulation for intraduodenal administration
ES2045470T3 (es) Formulaciones medicinales en aerosol.
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
ES2052016T3 (es) Composicion emulsionada.
ES2167453T3 (es) Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido.
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
ES2130217T3 (es) Uso de tiloxapol como dispersante y estabilizante de nanoparticulas.
PT850046E (pt) Microemulsoes para utilizacao como veiculos para administracao de compostos activos
ES2124791T3 (es) Composicion de liberacion en el sistema linfatico de un agente activo.
ES2031597T3 (es) Aparato distribuidor con un miembro dispensador para entregar un agente beneficioso.
MX9301435A (es) Metodo para producir dispositivos de suministro poroso.
AR030253A1 (es) Sistemas de suministro de drogas autoemulsionantes para drogas lipofilicas extremadamente insolubles en agua, una formulacion y el uso de una composicion para la fabricacion de un medicamento
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
DE69915733D1 (de) Kosmetische oder pharmazeutische Zusammensetzung in Form eines Feststoffs, welche verformt werden kann
ITMI922603A1 (it) Composizioni farmaceutiche comprendenti un farmaco, una sostanza polimerica reticolata, un olio ed un agente tensioattivo
MX9303604A (es) Procedimiento para la obtencion de formas farmauceticas retardadoras solidas.
ES2074269T3 (es) Preparado de suspension acuoso para inyeccion y metodo para producir el mismo.
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
CO5261494A1 (es) Composiciones farmaceuticas acuosas e hipotonicas de ciclesonida que presentan absorcion nasal mejorada
DE60002719D1 (de) Ophthalmische zusammensetzungen in form wässriger gele
IL105947A0 (en) Preparation for topical use,having light protection properties
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
ES2128353T3 (es) Composicion topica que contiene penciclovir.
MX9305554A (es) Agente antideslizante.
BR9509617A (pt) Composição de proteção à pele tópica em hidrogel translúcida

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 670713

Country of ref document: ES

SPCG Supplementary protection certificate granted

Free format text: PRODUCT NAME: LEVODOPOA+CARBIDOPA (DUEDOPA GEL INTESTINAL); NAT REG./DATE; 66547 20050203; FIRST REG.: SE 19210 20040121

Spc suppl protection certif: C200500023

Filing date: 20050418

Extension date: 20181129

Effective date: 20070521